Microalgal Cofactor Engineering Patents: Who Leads, White Space 2026
- 18 published records worldwide, with India (6 receiving-office filings) and the United States (5) carrying more activity than Europe or the PCT route.
- Filing growth of +100% from 2021 to 2024, the most recent year that can be read as complete once publication lag is accounted for.
- Claim activity concentrates in C12N and C12P, 94.4% and 77.8% of records respectively, leaving peptide, cosmetic and food-use branches thinly claimed.
Filing growth compares 2021 (1 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
Microalgal strain cofactor engineering sits at the intersection of strain genetics and metabolic redox control: patents here claim microalgal cells or recombinant microalgae engineered for NADH balance, NADPH supply, redox ratio management, cofactor recycling, electron transfer pathways, or energy charge — the internal bookkeeping that determines how efficiently a strain converts light or feedstock into lipids, fuels or fine chemicals. The scope is narrowed to records classified under microorganism culture (C12N1/12), fermentation and enzymatic synthesis (C12P1/00), or microbiological testing (C12Q1/04), so it excludes general algae cultivation patents that do not touch cofactor or redox mechanics directly.
The 18 records in scope span 2015 through the 2026 cut-off, with receiving-office activity spread across India, the United States, Europe and the PCT system. That footprint says more about where applicants expect to commercialise lipid and fermentation processes than about where the underlying science originated.
Filing trend and technology composition
Two views of the same 18-record dataset: how filing activity has moved year over year, and which IPC subclasses carry the claim weight.
A small field with a recent growth signal
Filings peaked at 6 in 2019, then thinned before recovering: 2021 recorded 1 filing and 2024 recorded 2, a +100% move over that span. Treat 2025 and 2026 counts as still filling in — publication typically lags filing by around 18 months, so the apparent drop toward the data cut-off is an artefact of that lag, not a real slowdown.
Claim weight sits on strain engineering and fermentation
C12N (microorganisms and genetic engineering) appears in 94.4% of the 18 records and C12P (fermentation and enzymatic synthesis) in 77.8%, confirming that most claims are written around the engineered organism itself and the process that exploits it. Peptide chemistry (C07K, 22.2%), horticulture (A01G, 11.1%), acyclic compounds (C07C, 11.1%), the C12R microorganism index (11.1%), food use (A23L, 5.6%) and cosmetic use (A61Q, 5.6%) each cover a handful of records — these are downstream application classes riding on the same core strains rather than independent claim territory.
Shares are the percentage of the 18 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microalgal Strain Cofactor Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about microalgal strain cofactor engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
US20220025414A1 — Microalgal strain and its use for the production of lipids
A microalgal strain of the species Nannochloropsis gaditana carries a mutation in an enzyme involved in chlorophyll biosynthesis, changing its physiology relative to the wild-type strain: lower chlorophyll content and reduced capacity to absorb visible light. A process cultivates the mutated strain for lipid production, with the resulting lipids usable as synthesis intermediates, including in green-chemistry applications.Filed by ENI S.p.A., published 2022-01-27.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20180066288A1 | Producing and altering microbial fermentation products using non-commonly used lignocellulosic hydrolysates | 5 |
| 2 | WO2018027181A1 | Producing and altering microbial fermentation products using non-commonly used lignocellulosic hydrolysates | 4 |
| 3 | WO2020115692A1 | Microalgal strain and its use for the production of lipids | 2 |
| 4 | US20220025414A1 | Microalgal strain and its use for the production of lipids | 1 |
| 5 | US20200172916A1 | Genetically modified alga, sequences and methods thereof | 1 |
Citation counts inside a searched corpus favour older filings that have had more time to accumulate references — read them as a signal of influence on later filings, not as a ranking of current commercial importance.
Publication numbers are shown where the record carries one (5 of 5 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three read-outs from the trend, composition and citation data that matter more than the raw counts on their own.
Growth is real but off a small base
The jump from 1 filing in 2021 to 2 in 2024 is the clearest complete-year signal in this dataset. It points to renewed interest in cofactor-level strain engineering after a quiet stretch following the 2019 peak of 6, but the absolute volume is still small enough that a handful of new filers could shift the picture quickly.
Core strain and fermentation claims dominate
Nearly every record touches genetic engineering of the organism itself, and most also claim the fermentation or synthesis process built on it. Downstream classes — peptides, cosmetics, food use — appear in only one or two records each, suggesting the commercial application layer is still open even where the underlying strain claims are dense.
Influence clusters on lignocellulosic fermentation art
The two most-cited records both concern producing and altering microbial fermentation products from non-commonly used lignocellulosic hydrolysates, filed as a US application and its WO counterpart. That pairing, rather than the microalgae-specific lipid filings, currently anchors the citation graph in this field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microalgal strain cofactor engineering, with the prior art for and against each one.
Assignee landscape
Eight companies make up the entire ranked list this dataset returns — not a top-50 or top-100 cut, the full set. The leader holds 4 records, fifth place holds 3, and momentum data shows no assignee posted a filing in the latest year, consistent with the 18-month publication lag rather than a stop in activity.
A single leader, no runaway concentration
The top-ranked assignee holds 4 of the 18 records, with fifth place close behind at 3 — a gap, not a gulf. Two co-assignee pairs (each linking 3 shared records) show that some of this leadership is joint work between an Indian government research body and a national oil company, and between an academic institute and a Singapore-based biotech.
Filing runs through institute-industry pairs
Both identified co-assignee relationships link a research or academic body to a commercial partner, each pair sharing 3 records. That pattern — public research institution paired with an operating company — is a more reliable predictor of who to watch than raw filing counts alone.
Latest-year counts read as zero across the board
Every assignee tracked for momentum shows 0 filings in the latest year, and two show a -100% year-on-year change. Given the 18-month gap between filing and publication, this is expected at the data cut-off and should not be read as the field going cold.
| Assignee | Recent year | YoY |
|---|---|---|
| ENI S.p.A. | 0 | — |
| Reliance Industries Limited | 0 | — |
| Department of Biotechnology (India) | 0 | — |
| Indian Oil Corporation | 0 | — |
| Indian Institute of Technology Madras | 0 | -100% |
| VAAYUNEER SCI PTE LTD | 0 | -100% |
| KUEHNLE AGROSYST | 0 | — |
| MANIPAL ACADEMY OF HIGHER EDUCATION | 0 | -100% |
Where to take this analysis
The trend and composition data point to a field that is small, growing off a low base, and thin in its application-layer claims. Turning that into a filing or freedom-to-operate decision takes a closer read of individual claim sets.
Map the white space claim by claim
The under-claimed branches above are visible at the IPC-subclass level; confirming they are actually open requires reading independent claims in the one or two records that occupy each class.
Explore white space in EurekaTrack the co-assignee pairs going forward
The two institute-industry pairs identified here are the most concentrated collaboration signal in the dataset; watching their future filings is a cheap early-warning system for this niche.
Set up assignee tracking in EurekaRe-run once 2025-2026 filings finish publishing
Because publication lags filing by roughly 18 months, the true 2025 filing count will not be visible for some time; a follow-up pull will sharpen the growth read beyond the 2021-2024 figure used here.
Schedule a refresh in EurekaCommon questions on this landscape
It covers patents on microalgal cells or recombinant microalgae where the claims address internal redox and energy bookkeeping — NADH balance, NADPH supply, redox ratio, cofactor recycling, electron transfer, or energy charge — rather than general cultivation or harvesting. In this dataset the scope is further narrowed to filings classified under microorganism culture (C12N1/12), fermentation and enzymatic synthesis (C12P1/00), or microbiological testing (C12Q1/04). A patent describing a mutated strain purely for faster growth, without a redox or cofactor mechanism in the claims, would sit outside this landscape even if it uses the same species.
The ranked list in this dataset contains 8 companies total, not a top-50 cut — it is the full set the search returns. The leading assignee holds 4 of the 18 records in scope, with the fifth-ranked assignee close behind at 3, so the field has a leader but not a runaway concentration. Two co-assignee pairs, each linking 3 shared records, show that some of the strongest activity is joint work between research institutions and commercial partners rather than any single company acting alone.
Reading only complete years, filings grew from 1 in 2021 to 2 in 2024, a +100% increase over that span, after an earlier peak of 6 in 2019. Counts for 2025 and 2026 appear low, but that reflects the roughly 18-month lag between when an application is filed and when it publishes, not a genuine drop in activity. Any assessment of whether the field is heating up or cooling off should rely on the 2021-2024 window rather than the most recent one or two years shown in a raw trend chart.
The core strain-engineering and fermentation-process claims are dense — C12N and C12P cover 94.4% and 77.8% of the 18 records respectively — but the application layer built on top of those strains is thin. Cosmetic use, food-grade formulations, peptide-level cofactor regulators, acyclic co-products and horticultural integration each appear in only one or two records. That combination, heavy core claims with light downstream application claims, is where a first mover could still stake out defensible ground.
India leads the receiving-office count at 6, ahead of the United States at 5, with Europe (EPO) and the WIPO PCT route each at 3 and Canada at 1. That distribution likely reflects where applicants — several of them Indian public research and energy institutions — expect to commercialise lipid and fermentation processes, alongside US filers pursuing the same strains for the American market. It does not necessarily indicate where the underlying research originated.
Research Microalgal Strain Cofactor Engineering in depth with Eureka
Go past this page: query the whole microalgal strain cofactor engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.